NO970030D0 - Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2 - Google Patents

Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2

Info

Publication number
NO970030D0
NO970030D0 NO970030A NO970030A NO970030D0 NO 970030 D0 NO970030 D0 NO 970030D0 NO 970030 A NO970030 A NO 970030A NO 970030 A NO970030 A NO 970030A NO 970030 D0 NO970030 D0 NO 970030D0
Authority
NO
Norway
Prior art keywords
hla
nucleic acid
acid sequence
sequence encoding
isolated nucleic
Prior art date
Application number
NO970030A
Other languages
English (en)
Norwegian (no)
Other versions
NO970030L (no
Inventor
Vincent Brichard
Aline Van Pel
Pierre Coulie
Thierry Boon-Falleur
Etienne De Plaen
Catia Traversari
Thomas Wolfel
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of NO970030L publication Critical patent/NO970030L/no
Publication of NO970030D0 publication Critical patent/NO970030D0/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO970030A 1994-07-08 1997-01-06 Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2 NO970030D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27235194A 1994-07-08 1994-07-08
US08/370,319 US5856091A (en) 1993-03-18 1995-01-10 Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
PCT/US1995/008153 WO1996001557A1 (en) 1994-07-08 1995-06-27 Isolated nucleic acid sequence coding for a tumor rejection antigen presented by hla-a2

Publications (2)

Publication Number Publication Date
NO970030L NO970030L (no) 1997-01-06
NO970030D0 true NO970030D0 (no) 1997-01-06

Family

ID=26955454

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970030A NO970030D0 (no) 1994-07-08 1997-01-06 Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2

Country Status (10)

Country Link
US (2) US5856091A (fi)
EP (1) EP0772626A4 (fi)
JP (1) JPH10503928A (fi)
CN (1) CN1152251A (fi)
AU (1) AU696738B2 (fi)
CA (1) CA2194451A1 (fi)
FI (1) FI970071A0 (fi)
NO (1) NO970030D0 (fi)
NZ (1) NZ289616A (fi)
WO (1) WO1996001557A1 (fi)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856091A (en) * 1993-03-18 1999-01-05 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US6013481A (en) * 1993-07-22 2000-01-11 Ludwig Institute For Cancer Research Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
EP0756604A1 (en) * 1994-04-22 1997-02-05 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Melanoma antigens
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
US5674749A (en) * 1996-03-26 1997-10-07 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor melan-A, and uses thereof
JP2001503966A (ja) * 1996-06-25 2001-03-27 ザ ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 脳グリコーゲンホスホリラーゼ癌抗原
US6080399A (en) * 1998-04-23 2000-06-27 Arch Development Corporation Vaccine adjuvants for immunotherapy of melanoma
WO2008039818A2 (en) * 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
ES2729759T3 (es) * 2012-07-12 2019-11-06 Persimmune Inc Vacunas contra el cáncer personalizadas y terapias celulares inmunitarias adoptivas
JP6510029B2 (ja) * 2014-07-15 2019-05-08 イラミーナ インコーポレーテッド 生化学的に作動する電子デバイス
US10987045B2 (en) 2015-09-14 2021-04-27 Biosense Webster (Israel) Ltd. Basket catheter with individual spine control

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3297893A (en) 1963-09-19 1967-01-10 Litz Co Brush mechanisms
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5856091A (en) * 1993-03-18 1999-01-05 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods

Also Published As

Publication number Publication date
FI970071A (fi) 1997-01-07
NO970030L (no) 1997-01-06
CN1152251A (zh) 1997-06-18
AU696738B2 (en) 1998-09-17
AU2951795A (en) 1996-02-09
WO1996001557A1 (en) 1996-01-25
US6201111B1 (en) 2001-03-13
CA2194451A1 (en) 1996-01-25
FI970071A0 (fi) 1997-01-07
EP0772626A4 (en) 1997-09-10
NZ289616A (en) 1997-12-19
US5856091A (en) 1999-01-05
JPH10503928A (ja) 1998-04-14
EP0772626A1 (en) 1997-05-14

Similar Documents

Publication Publication Date Title
FI914908A0 (fi) Ny monoklonal antikropp med ny antigen relaterad till humana tumoerer.
DE69009729D1 (de) Tonerfixierungsverfahren.
DK296189A (da) Nucleinsyresekvenser, som koder for peptidsekvenser af carcinoembryonisk antigen-familien
FI901256A0 (fi) Formulationer som administreras genom slemhinna.
NO884771D0 (no) Fremgangsmaate for fremstilling av et kimerisk antistoffmolekyl.
NO880395D0 (no) Antigener.
DE3750351T4 (de) Magnetischer Toner.
NO970030D0 (no) Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2
MX26688A (es) Procedimiento para preparar un polen transgenetico
FI862761A0 (fi) Klonad antigen.
IT1197625B (it) Antigene di picornavirus sintetico
DK163062C (da) Antigen, immunogen, proteinholdig vaccine imod coccidiose
DE3687487T2 (de) Monoklonaler antikoerper, spezifisch fuer ein pigmentationassoziiertes antigen.
DK169987D0 (da) Human tumor-associated antigen, ca-ou1
DK614388A (da) Fotohaerdnelig, elektrostatisk master med hoej oploesning
DE69017343T2 (de) Magnetischer Toner.
DE59003454D1 (de) Schubzentrifuge.
FI890852A (fi) Pneumatisk patron.
NO851386L (no) Fremgangsmaate for fremstilling av antigen.
DK448687D0 (da) Dna, der koder for et virusantigen
NO901587D0 (no) Syntetisk dna-sekvens som koder for humaninsulinlignende vekstfaktor ii.
NO885392D0 (no) Humant tumor-assosiert antigen.
DK182188D0 (da) Humant tumorassocieret antigen
ZA955676B (en) Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
ATE94171T1 (de) Geaenderte antikoerper.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application